Abbott Laboratories (ABT) Q4 2024 Earnings Call Transcript
Welcome to Abbott's fourth quarter 2024 earnings conference call. [Operator instructions] This call is being recorded by Abbott. With the exception of any participants' questions asked during the question-and-answer session,
Abbott Laboratories Will Outperform Healthcare Stocks in 2025
The outlook and technical action suggest Abbott Laboratories (NYSE: ABT) will lead healthcare names like Johnson & Johnson (NYSE: JNJ) higher in 2025. While each produced a solid quarter, Abbott Laboratories outperformed and has a more robust outlook.
Why Abbott Laboratories (ABT) Stock is Currently 2.73% Above from Its 20-Day SMA?
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.66% of Abbott Laboratories (ABT)’s shares, while financial institutions hold 76.57%.
Abbott Laboratories stock outperforms competitors on strong trading day
Shares of Abbott Laboratories rose 4.62% to $123.22 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 0.53% to 6,118.71 and the Dow Jones Industrial Average rising 0.
Abbott Laboratories Stock Turns Positive. What to Know From Its Earnings.
Abbott Laboratories posts total worldwide sales of $10.97 billion for the quarter ended Dec. 31, missing Wall Street estimates of $11.03 billion.
Abbott Laboratories' SWOT analysis: stock poised for growth amid challenges
Abbott Laboratories (NYSE: NYSE:ABT) has demonstrated resilience and growth potential in the healthcare sector, maintaining a strong financial profile despite facing various challenges. According to InvestingPro data,
Abbott Q4 Earnings Meet, Margins Down, Stock Falls in Pre-Market
Abbott Laboratories ABT reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.34, in line with the Zacks ...
RBC Capital Sticks to Its Buy Rating for Abbott Laboratories (ABT)
In a report released yesterday, Shagun Singh Chadha from RBC Capital reiterated a Buy rating on Abbott Laboratories (ABT – Research Report), ...
bovnews1d
Abbott’s (ABT) Impressive Q4 and Bold Projections for 2025: What You Need to Know
The company’s projected adjusted diluted EPS for 2025 is between $5.05 and $5.25, marking double-digit growth at the midpoint. Abbott’s first-quarter 2025 adjusted EPS is expected to be between $1.05 ...
Yahoo Finance5d
Jim Cramer on Abbott Laboratories (ABT): ‘I Think Abbott Will Win These Baby Formula Cases’
In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against the other stocks on Jim Cramer's radar. Jim Cramer, host of Mad Money, recently emphasized the ...
Analysts Are Bullish on Top Healthcare Stocks: Abbott Laboratories (ABT), Arrowhead Pharmaceuticals (ARWR)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Abbott Laboratories (ABT – Research Report), ...
Abbott Labs Q4 Earnings And Q1 Profit Guidance Lags Street View, Worldwide COVID-19 Testing Sales Fall
Abbott's Q4 sales reached $10.97 billion, with 8.8% organic growth. EPS met expectations at $1.34, driven by strong ...
MassDevice1d
Abbott sales come up just shy of Q4 expectations on Wall Street, highlights EP growth
Abbott reported fourth-quarter results that missed the consensus sales forecast — but medical device sales remain a bright ...
Abbott Laboratories: Solid Performance in Key Sectors but Hold Rating Due to Mixed Outlook
Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target of ...